title: The use of natalizumab for treatment of MS: do the risks still outweigh the gains?
authors.forename: Mark
authors.initials: M
authors.lastname: Freedman
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D006801:Humans; D039441:Integrin alpha4 / Q000276:immunology; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab; D039441:Integrin alpha4